New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard
Therapy in Treatment of Hypertension
-FIXED DOSE COMBINATION WITH DIURETIC ACCEPTED FOR REVIEW BYFDA- BASEL, Switzerland and BRIDGEWATER, NJ, 21 May 2007 -Speedel (SWX: SPPN) today welcomed the significant new results fromclinical trials of SPP100 (aliskiren,
Tekturna/Rasliez[1])presented by investigators at the 22nd Annual Scientific Meetingand Exposition of the American Society of Hypertension (ASH) inChicago, IL,...
Tekturna, First New Type of High Blood Pressure Medicine in a
Decade, Provides Additional Blood Pressure Reduction When Used With
Diovan
* New study results show more patients receiving both
Tekturna andDiovan reached target blood pressure goal compared to those takingeither agent alone EAST HANOVER, N.J., March 26, 2007 /PRNewswire/ -- Results froma new study have shown patients taking two Novartis cardiovascularmedicines -- the recently U.S.-approved drug
Tekturna(R)(aliskiren) and the leading therapy Diovan(R) (valsarta...